Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurosurg Rev. 2012 Jan;35(1):1-13; discussion 13-4. doi: 10.1007/s10143-011-0354-1. Epub 2011 Oct 18.

Current therapeutic options and novel molecular markers in skull base chordomas.

Author information

1
Department of Neurosurgery, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy. gagliardi.filippo@hsr.it

Abstract

Chordomas are extremely rare tumours. They arise in the spheno-occipital region in 35% of cases. Chordomas usually present benign histopathological features but often exhibit a malignant clinical behaviour. Radical surgical removal and high-dose radiation therapy seem to be effective in tumour control and to improve survival rate. Despite the advancements in microsurgical techniques and the development of radiation therapies, clival chordomas still represent a challenge. Nevertheless it appears that chordomas that have been resected to the same extent and that received post-operative radiotherapy might exhibit different rates of regrowth. This result supports the hypothesis that the recurrence rate of chordomas might be dependent on biological variables other than the extent of resection and the post-operative radiotherapy. Genetic and molecular studies on oncogenesis of chordomas are still limited, but they represent the basis for the development of molecular targeted therapies. We present a review of the current knowledge about skull base chordomas biology, therapeutic options and related clinical outcome.

PMID:
22006091
DOI:
10.1007/s10143-011-0354-1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center